Publication at First Faculty of Medicine, Third Faculty of Medicine |
2013
Abstract
Deep vein thrombosis is a common disease with serious prognosis (the risk of death or crippling pulmonary embolism or development of post-thrombotic syndrome). In etiopathogenesis of the thrombotic condition in cases of phlebothrombosis, acquired or innate hyper-coagulation conditions, damage to the blood vessel walls and venous stasis all play role.
Which means that the logical choice of treatment for both therapeutic and prophylactic purposes is anticoagulation therapy. Apart from warfarin, heparin and drugs derived from those, which have been used in prophylaxis and treatment for many years, new oral anticoaglants (NOAC) are coming to the forefront.